DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of DBV Technologies (NASDAQ:DBVT) in a report issued on Sunday. The brokerage set a “hold” rating on the stock.

Separately, HC Wainwright reduced their price target on shares of DBV Technologies from $20.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th.

DBV Technologies Price Performance

NASDAQ:DBVT opened at $0.97 on Friday. DBV Technologies has a 12 month low of $0.84 and a 12 month high of $4.42. The firm has a market capitalization of $93.60 million, a PE ratio of -1.15 and a beta of 0.69. The business’s fifty day moving average price is $1.16 and its 200 day moving average price is $1.50.

DBV Technologies (NASDAQ:DBVT) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.28) earnings per share for the quarter, topping the consensus estimate of ($0.44) by $0.16. DBV Technologies had a negative net margin of 530.89% and a negative return on equity of 56.76%. The business had revenue of $1.41 million during the quarter, compared to the consensus estimate of $3.20 million. As a group, equities analysts anticipate that DBV Technologies will post -1.22 EPS for the current year.

Hedge Funds Weigh In On DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. boosted its holdings in DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,568,909 shares of the company’s stock after acquiring an additional 327,345 shares during the quarter. DBV Technologies comprises approximately 0.2% of Yiheng Capital Management L.P.’s portfolio, making the stock its 15th biggest holding. Yiheng Capital Management L.P. owned about 2.89% of DBV Technologies worth $4,172,000 as of its most recent SEC filing. 71.74% of the stock is currently owned by institutional investors.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.